October

30
2009

11:00 am EDT - 12:00 pm EDT

Past Event

Brookings Roundtable on Active Medical Product Surveillance

  • Friday, October 30, 2009

    11:00 am - 12:00 pm EDT

The Brookings Institution
Teleconference Call

1775 Massachusetts Ave., NW
Washington, DC

This event was the first of a new series of roundtable teleconferences on active medical product surveillance – providing a forum to discuss public and private initiatives in which methods, data sources, and technology related to active medical product surveillance are being developed.

The call featured an update from FDA leaders on their active surveillance activities, as well as a moderated question and answer period following the FDA’s presentations.

Convened by the Engelberg Center for Health Care Reform at Brookings and suppored by a grant from the Food and Drug Administration.

Agenda

  • October 30
    • Welcome and Introduction

      Mark B. McClellan Former Brookings Expert, Director, Margolis Center for Health Policy - Duke University
    • Update on FDA Active Surveillance Efforts

      JR
      Judy Racoosin Sentinel Initiative Scientific Lead, Office of Medical Policy, Center for Drug Evaluation and Research
      JS
      Judy Staffa Associate Director for Regulatory Research, Office of Surveillance and Epidemiology, Center for Drug Evaluation and Research, FDA
      BB
      Bob Ball Medical Officer IV, Division of Epidemiology, Office of Biostatistics and Epidemiology, Center for Biologics Evaluation and Research, FDA
      TS
      Tom Scarnecchia Executive Director, Observational Medical Outcomes Partnership, FNIH
    • Roundtable Discussion and Questions

      Mark B. McClellan Former Brookings Expert, Director, Margolis Center for Health Policy - Duke University
    • Wrap-Up and Next Steps

      Mark B. McClellan Former Brookings Expert, Director, Margolis Center for Health Policy - Duke University